查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829114

免疫腫瘤學檢測市場（按技術類型、產品、樣本類型、最終用戶、適應症和應用）—全球預測，2025-2032

Immuno Oncology Assays Market by Technology Type, Product, Sample Type, End User, Indication, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年免疫腫瘤檢測市場規模將成長至 231.6 億美元，複合年成長率為 15.69%。

主要市場統計數據
基準年2024年 72.1億美元
預計2025年 83.3億美元
預測年份：2032年 231.6億美元
複合年成長率（%） 15.69%

權威介紹，闡述免疫腫瘤學檢測在研究、臨床開發和診斷用例中的戰略重要性和範圍

免疫腫瘤學檢測正處於快速發展的生物學理解和日益複雜的測量技術的交匯點。本介紹重點介紹了該領域當前的重點：提高檢測靈敏度和特異性、整合多體學讀數以及將實驗室發現轉化為臨床可操作的工具。本報告還將分析影響開發和商業化路徑的技術，包括技術發展、產品差異化、樣本處理考量、最終用戶採用模式以及應用主導的用例。

本節將揭示免疫腫瘤學檢測為何在現代腫瘤學研究和治療開發中佔據核心地位。從早期生物標記發現到伴隨診斷，再到臨床試驗中的免疫監測，檢測方法都是客觀決策的基石。報告始終強調可重複性、監管合規性和營運擴充性，這些因素決定了一項技術能否從探索性應用轉向常規部署。引言部分概述了後續章節如何提供涵蓋技術、商業性和區域層面的策略背景，以支持投資者、開發者和從業者的決策。

技術、監管和商業性變革的綜合體將重塑檢測方法的發展，並加速轉化和臨床應用

過去幾年，免疫腫瘤學檢測的科學和商業性格局發生了翻天覆地的變化。單細胞解析度、多重蛋白質檢測和高通量定序的進步，共同擴展了可測量免疫表現型的範圍。同時，曾經主要用作研究工具的平台，正透過改善自動化、標準化和品管，朝向臨床級應用邁進。

同時，支持檢測開發的生態系統也在改變。儀器製造商、試劑供應商和受託研究機構之間的夥伴關係正變得更加策略化和垂直整合。當偵測工作流程的設計考慮到最終使用者的限制（例如樣本量有限、臨床交付壓力以及可互通資料輸出的需求）時，這種趨勢會加速。監管期望也在不斷發展，要求開發人員在開發早期就證明分析的有效性、臨床相關性和強大的品管系統。這些共同的變化創造了一個環境：如果新的檢測方法要充分發揮其在研究和患者照護的潛力，技術創新必須與操作嚴謹性相匹配，並有明確的應用路徑。

不斷變化的關稅動態如何推動供應鏈彈性、供應商多樣化以及檢測採購和製造的本地化策略

貿易政策的變化和關稅調整，為營運全球供應鏈並向臨床和研究實驗室部署檢測試劑的組織帶來了額外的複雜性。關稅波動會影響設備和耗材的籌資策略，影響供應商多元化、區域庫存分期和在地化製造能力的決策。許多組織正在權衡跨境採購的營運成本與維持專用試劑和設備的戰略價值，而這些試劑和設備可能只能從有限的全球供應商處獲得。

作為應對，相關人員正在採取各種緩解措施。一些機構正在重新評估供應商契約，並簽訂長期協議以穩定價格和供應。另一些機構則加快替代供應商的資格審查流程，或投資本地製造合作夥伴和委託製造製造商，以降低關稅導致的成本波動風險。此外，採購和供應鏈團隊正在與研發和臨床營運部門更緊密地合作，優先考慮關鍵零件，並設計出更少依賴單一供應商的檢測方法。這些調整旨在保持研究和臨床項目的連續性，同時在不斷變化的貿易政策中保持合規性和成本效益。

詳細的細分洞察揭示了技術平台、產品類型、樣品類型、最終用戶需求、適應症和應用之間的相互作用如何影響檢測優先級

細分市場層面的動態揭示了創新、採用和商業性緊張局勢在技術類型、產品類型、樣本格式、最終用戶需求、適應症和應用方面的交匯點。在技​​術領域，流式細胞技術等成熟技術與質譜流式細胞儀和次世代定序儀共存，各有優勢。雖然傳統流式細胞技術仍然是表現型分析的主要手段，但頻譜流式細胞技術擴展了連接複用能力，而質譜流式細胞儀能夠進行高度參數分析，從而進行深度免疫表現型分析。免疫測量形式不斷發展，從傳統的 ELISA 演變為連接複用免疫測量，從而提供更廣泛的細胞激素組和更高的通量。次世代定序儀方法包括針對免疫相關基因座客製化的靶向組、提供更廣泛基因組圖譜的全外EXOME組測序以及用於全面分析的全基因組測序，每一層都在深度、廣度和成本之間取得平衡。

耗材包括探針、抗體、試劑和試劑套件，必須針對批間一致性和檢測特異性進行最佳化。儀器包括支援高通量工作流程的自動化系統和基於平台的儀器，旨在靈活用於多種檢測類型。基於血液的檢測提供微創縱向監測，細胞株工作流程促進機制發現，基於組織的檢測提供腫瘤微環境分析所必需的空間和背景資訊。最終用戶的優先順序各不相同：包括研究機構和大學在內的學術和研究機構優先考慮檢測靈活性和新穎的讀數；診斷實驗室強調法規遵從性和通量；醫院和診所要求快速週轉和臨床效用；製藥和生物技術公司優先考慮檢測的可重複性和與臨床試驗工作流程的整合。乳癌、血液癌、肺癌和黑色素瘤的檢測各自面臨不同的組織可用性、生物標記特徵和臨床終點。按應用進行細分，例如生物標記發現、伴隨診斷、細胞激素分析、免疫監測和腫瘤微環境分析，確定檢測性能閾值和數據解釋框架，並告知該方法是否最適合發現研究、診斷開發或臨床試驗。

綜合考慮這些環節，我們發現，成功的檢測策略需要將技術選擇、產品設計和操作執行與特定的樣本環境、最終用戶工作流程和治療適應症相結合。在檢測標準化、跨平台數據協調和以用戶為中心的自動化方面的過渡性投資，將彌補有前景的方法與廣泛應用之間的差距。

區域比較洞察，展示美洲、歐洲、中東和非洲以及亞太地區的市場特徵如何影響採用、檢驗和商業化策略

區域特徵對檢測方法的開發重點、商業化策略和合作有顯著的影響。在美國，產學合作和成熟的臨床試驗基礎設施支持新型檢測方法快速推進至臨床試驗階段，而美國的監管途徑和報銷機制則指導伴隨診斷​​的設計和驗證。該地區的創投和企業投資活動通常會加速平台技術的擴展，而靠近大型臨床網路的優勢則有利於開展廣泛的臨床檢驗計畫。

歐洲、中東和非洲呈現出一種多元化的格局，協調一致的監管環境、跨境研究合作以及國家醫療保健體系既帶來了機遇，也帶來了複雜性。歐洲研究中心經常主導以免疫分析和腫瘤微環境表徵為重點的多中心研究，但開發人員必須考慮不同司法管轄區不同的監管預期和報銷框架。在中東和非洲，對研究能力和臨床基礎設施的投資不斷成長，正在催生對可在集中實驗室進行的、可靠且可擴展的檢測方法的新興需求。

亞太地區正經歷科學研究產出的快速成長、臨床試驗的增加以及對本地生產和產能建設的高度重視。一些國家正在優先發展生物技術和生命科學項目，培育支持檢測創新以及試劑和設備本地生產的生態系統。該地區還提供了製定個人化診斷策略的機會，這些策略能夠反映特定人群的疾病生物學和醫療保健服務模式。在整個地區，跨境合作和數位資料共用工作正在加速方法標準化和最佳實踐的傳播。

主要企業層面動態，說明平台模組化、試劑品質、策略夥伴關係和服務模式如何塑造競爭優勢和採用路徑

產業參與者正透過結合專有檢測化學方法、整合平台和服務導向模式來脫穎而出。同時，試劑和耗材供應商則專注於抗體驗證、試劑穩定性和批次間一致性，以減少下游數據差異。受託研究機構和專業服務供應商正在成為缺乏內部能力進行大規模免疫監測或複雜組織檢測的機構的策略合作夥伴，提供檢測開發、樣本處理和數據分析等一站式服務。

診斷公司與製藥贊助商之間的合作正變得越來越普遍，這得益於伴隨診斷對患者分層和支持治療核准途徑的需求。同時，規模較小的創新者正在利用高度連接複用的檢測方法、先進的單細胞分析或針對特定臨床工作流程的精簡自動化技術開拓市場。跨部門夥伴關係，包括學術衍生公司和共同開發契約，在提高檢測穩健性和加速臨床驗證方面發揮核心作用。總體而言，競爭態勢強調互通性、品質保證以及提供端到端解決方案的能力，以減少臨床和轉化應用的障礙。

為產業領導者提供加速採用的可行建議，重點在於驗證嚴謹性、以工作流程為中心的設計、供應鏈彈性、監管參與和資料協調

該領域的領導者應優先考慮一系列切實可行的措施，將創新轉化為營運效益。首先，投資嚴格的檢測驗證途徑，以解決分析性能、實驗室間重現性和試劑可追溯性問題。這項基礎性工作可以降低下游臨床風險，並簡化監管流程。自動化、使用者友善軟體以及與實驗室資訊系統的互通性將加速該技術在診斷和臨床環境中的應用。第三，透過對多家供應商進行資格審查、探索區域製造夥伴關係夥伴關係以及維持關鍵試劑的策略性庫存緩衝來增強供應鏈的韌性，以減輕貿易政策變化和物流限制造成的中斷。

第四，儘早與臨床和監管相關人員溝通，使驗證計畫與核准和報銷預期保持一致。第五，與學術中心和合約研究組織 (CRO) 建立夥伴關係，以支持多中心驗證研究並獲得多樣化的患者群體。第六，投資於數據協調和生物資訊學專業知識，以便從複雜的多組體學檢測中獲得臨床可解釋的結果。協調實施這些建議將提高新檢測方法獲得科學可信度並實用化為研究和臨床實踐的可能性。

透明的、專家主導的調查方法結合了相關人員訪談、技術綜合和迭代專家評審，確保了可操作且可辯護的發現

本分析所採用的調查方法結合了主要相關人員訪談、二手文獻整合和跨職能專家評審，以確保研究的嚴謹性和有效性。主要資訊包括對科研領導者、實驗室主任和公司高管的訪談，他們就檢測性能、部署挑戰和應用促進因素提供了第一手的觀點。這些定性見解與技術文獻和監管指南相互參考，從而基於當前的最佳實踐和新興標準得出結論。

分析方法著重於技術的比較評估、產品生命週期考量的評估以及基於情境的供應鏈和監管變數探索。特別關注可重複性基準、驗證框架以及在學術、臨床和商業性環境中的實施障礙。專家對研究結果進行反覆審核，以完善其策略意義，並將其轉化為致力於檢測方法開發、商業化和臨床整合的相關人員的可行建議。

結論：技術進步、營運限制和策略要求的綜合將決定哪些免疫腫瘤學檢測將實現臨床和商業性影響

總而言之，免疫腫瘤學檢測正從最初的探索性套件包轉變為一套臨床相關、操作可擴展的解決方案，這些解決方案將對治療方法開發和患者護理產生重大影響。多分析物檢測、單細胞分析、定序深度和自動化技術的整合擴展了可測量和可解釋的範圍，而供應鏈現狀和監管期望決定了檢測的開發和部署方式。成功的策略將在技術目標與驗證、可重複性和最終用戶工作流程整合等實際考量之間取得平衡。

展望未來，那些投資於強大的檢測驗證、建立戰略夥伴關係並設計出能夠解決現實世界臨床和實驗室限制的解決方案的機構，將最有能力將科學進步轉化為可衡量的臨床和商業性價值。能夠跨平台協調數據並將複雜的多維讀數轉化為具有臨床意義的洞察，將成為該領域領導者的關鍵能力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合高內涵成像分析，同時分析腫瘤微環境中的免疫細胞表現型與功能
  • 開發基於液態生物檢體的檢測方法，用於非侵入性監測癌症患者免疫查核點抑制劑的療效
  • 擴展多重細胞激素分析平台，以便即時詳細評估免疫療法誘導的生物標記
  • 單細胞定序分析在表徵免疫治療中的T細胞受體多樣性和克隆性方面的進展
  • 標準化 PD-L1 IHC 檢測與數位病理學相結合的商業化提高了預測準確性
  • 新興的基於抗原的胜肽增殖檢測方法，用於個人化癌症疫苗開發和患者選擇
  • 在免疫檢測中採用自動化和微射流來提高臨床試驗環境中的通量和可重複性
  • 針對新型免疫查核點標靶和組合的伴隨診斷免疫檢測的監管指南不斷發展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 免疫腫瘤學檢測市場（依技術類型分類）

  • 流式細胞技術
    • 常規流式細胞技術
    • 頻譜流式細胞技術
  • 免疫檢測
    • ELISA
    • 多重免疫檢測
  • 質譜流式細胞儀
  • 次世代定序
    • 目標面板
    • 全EXOME定序
    • 全基因測序

9. 免疫腫瘤學檢測市場（按產品）

  • 耗材
    • 探針和抗體
    • 試劑和套件
  • 裝置
    • 自動化系統
    • 平台型設備

第 10 章。免疫腫瘤學檢測市場（依樣本類型）

  • 血
  • 細胞株
  • 組織

第 11 章。免疫腫瘤學檢測市場（按最終用戶）

  • 學術和研究機構
    • 研究所
    • 大學
  • 診斷實驗室
  • 醫院和診所
  • 製藥和生物技術

第 12 章：免疫腫瘤學檢測市場（按適應症）

  • 乳癌
  • 血癌
  • 肺癌
  • 黑色素瘤

第13章 免疫腫瘤學檢測市場（依應用）

  • 生物標記發現
  • 伴隨診斷
  • 細胞激素分析
  • 免疫監測
  • 腫瘤微環境分析

第 14 章。免疫腫瘤學檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章。免疫腫瘤學檢測市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章：各國免疫腫瘤學檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Reaction Biology Corporation
    • Bio-Rad Laboratories, Inc.
    • Creative Biolabs
    • QIAGEN NV
    • Illumina, Inc.
    • Becton, Dickinson and Company
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market is projected to grow by USD 23.16 billion at a CAGR of 15.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.21 billion
Estimated Year [2025] USD 8.33 billion
Forecast Year [2032] USD 23.16 billion
CAGR (%) 15.69%

An authoritative introduction framing the strategic importance and scope of immuno-oncology assays across research, clinical development, and diagnostic use cases

The immuno-oncology assays landscape sits at the intersection of rapidly advancing biological understanding and increasingly sophisticated measurement technologies. This introduction frames the field's contemporary priorities: improving assay sensitivity and specificity, integrating multi-omic readouts, and translating laboratory discoveries into clinically actionable tools. It also establishes the report's remit to analyze technology evolution, product differentiation, sample handling considerations, end-user adoption patterns, and application-driven use cases that shape development and commercialization pathways.

This section underscores why immuno-oncology assays are central to modern oncology research and therapeutic development. From early-stage biomarker discovery through companion diagnostics and immune monitoring in clinical trials, assays serve as the backbone of objective decision-making. Throughout the report, emphasis is placed on reproducibility, regulatory alignment, and operational scalability as determinants of whether a technique moves from exploratory use to routine deployment. The introduction closes by outlining how subsequent sections will provide strategic context across technological, commercial, and regional dimensions to support investor, developer, and practitioner decision-making.

A synthesis of the transformative technological, regulatory, and commercial shifts reshaping assay development and accelerating adoption across translational and clinical settings

The past several years have witnessed transformative shifts that reconfigure both the scientific and commercial contours of immuno-oncology assays. Advances in single-cell resolution, multiplexed protein detection, and high-throughput sequencing have converged to expand the range of measurable immune phenotypes. At the same time, platforms that once served primarily as research tools are evolving toward clinical-grade implementations through improved automation, standardization, and quality control practices.

Concurrently, the ecosystem supporting assay deployment is changing; partnerships between instrument manufacturers, reagent suppliers, and contract research organizations are becoming more strategic and vertically integrated. This trend accelerates when assay workflows are designed with end-user constraints in mind, such as limits on sample volume, turnaround time pressures in clinical settings, and the need for interoperable data outputs. Regulatory expectations are also evolving, pushing developers to demonstrate analytical validity, clinical relevance, and robust quality management systems earlier in development. Together, these shifts create an environment where technological innovation must be matched by operational rigor and clear pathways to adoption if new assay modalities are to realize their potential in research and patient care.

How evolving tariff dynamics are prompting supply chain resilience, supplier diversification, and localization strategies for assay procurement and manufacturing

Trade policy changes and tariff adjustments have introduced additional layers of complexity for organizations operating global supply chains and deploying assays across clinical and research laboratories. Tariff dynamics influence sourcing strategies for instruments and consumables, affecting decisions about supplier diversification, regional inventory staging, and the localization of manufacturing capabilities. Many organizations now weigh the operational costs of cross-border procurement against the strategic value of maintaining access to specialized reagents and instruments that may be available only from a limited set of global suppliers.

In response, stakeholders are adopting a range of mitigations. Some are re-evaluating supplier agreements and entering into longer-term contracts to stabilize pricing and availability. Others are accelerating qualification procedures for alternative suppliers and investing in local manufacturing partners or contract manufacturers to reduce exposure to tariff-induced cost volatility. Additionally, procurement and supply chain teams are collaborating more closely with R&D and clinical operations to prioritize critical components and design assays that are less dependent on single-source inputs. These adaptations aim to preserve continuity of research and clinical programs while maintaining compliance and cost-effectiveness in the face of shifting trade policies.

Detailed segmentation insights revealing how technology platforms, product types, sample formats, end-user needs, indications, and applications interact to shape assay prioritization

Segment-level dynamics reveal where innovation, adoption, and commercial tension intersect across technology types, product categories, sample formats, end-user needs, indications, and applications. Within technology, established modalities such as flow cytometry coexist with mass cytometry and next-generation sequencing, each offering distinct strengths. Conventional flow cytometry remains a workhorse for phenotyping while spectral flow cytometry extends multiplexing capacity, and mass cytometry enables very high parameter profiling for deep immune phenotyping. Immunoassay formats continue to evolve from traditional ELISA toward multiplex immunoassays that deliver broader cytokine panels and higher throughput. Next-generation sequencing approaches span targeted panels tailored to immune-related loci, whole exome sequencing that provides broader genomic context, and whole genome sequencing for comprehensive analyses, with each tier balancing depth, breadth, and cost considerations.

Product segmentation differentiates consumables from instruments, where consumables encompass probes, antibodies, reagents, and kits that must be optimized for lot-to-lot consistency and assay specificity, and instruments include both automated systems that support high-throughput workflows and platform-based instruments designed for flexible use across multiple assay types. Sample type considerations influence workflow design and assay selection; blood-based assays offer minimally invasive longitudinal monitoring, cell line workstreams drive mechanistic discovery, and tissue-based assays provide spatial and contextual information critical for tumor microenvironment analysis. End users present varying priorities: academic and research institutes, including both research institutes and universities, prioritize assay flexibility and novel readouts, diagnostic laboratories emphasize regulatory compliance and throughput, hospitals and clinics require rapid turnaround and clinical utility, and pharmaceutical and biotech organizations focus on assay reproducibility and integration into clinical trial workflows. Indication-specific needs shape validation strategies and selection criteria; assays for breast cancer, hematologic cancers, lung cancer, and melanoma each confront distinct tissue availability, biomarker signatures, and clinical endpoints. Application-driven segmentation-biomarker discovery, companion diagnostics, cytokine analysis, immune monitoring, and tumor microenvironment analysis-dictates assay performance thresholds and data interpretation frameworks, informing whether an approach is most suitable for exploratory research, diagnostic development, or clinical trial readouts.

Taken together, these segment dimensions illustrate that successful assay strategies are those that align technology choice, product design, and operational execution with specific sample contexts, end-user workflows, and therapeutic indications. Transitional investments in assay standardization, cross-platform data harmonization, and user-centric automation bridge the gap between promising methods and widespread adoption.

Comparative regional insights illustrating how Americas, Europe Middle East & Africa, and Asia-Pacific market characteristics influence adoption, validation, and commercialization strategies

Regional characteristics exert strong influence on assay development priorities, commercialization strategies, and collaborative landscapes. In the Americas, academic-industry partnerships and a mature clinical trials infrastructure support rapid translation of novel assays into trial settings, while U.S. regulatory pathways and reimbursement dynamics guide the design and validation of companion diagnostics. Venture and corporate investment activity in this region often accelerates the scaling of platform technologies, and proximity to large clinical networks enables extensive clinical validation programs.

Europe, the Middle East & Africa exhibits a heterogeneous landscape where regulatory harmonization efforts, cross-border research collaborations, and national healthcare systems create both opportunities and complexities. European centers of excellence frequently lead multicenter studies focused on immune profiling and tumor microenvironment characterization, but developers must account for diverse regulatory expectations and reimbursement frameworks across jurisdictions. The Middle East and Africa are experiencing growing investments in research capacity and clinical infrastructure, creating nascent demand for robust, scalable assays that can be deployed in centralized laboratories.

Asia-Pacific is marked by rapidly expanding research output, increasing clinical trial activity, and an emphasis on local manufacturing and capacity building. Several countries are prioritizing biotech and life science initiatives, fostering ecosystems that support assay innovation and localized production of reagents and instruments. The region also presents opportunities for tailored diagnostic strategies that reflect population-specific disease biology and healthcare delivery models. Across all regions, cross-border collaborations and digital data sharing initiatives are helping to standardize methodologies and accelerate dissemination of best practices.

Key company-level dynamics showing how platform modularity, reagent quality, strategic partnerships, and service models are shaping competitive advantage and adoption pathways

Industry participants are forging differentiated positions through a combination of proprietary assay chemistries, integrated platforms, and service-oriented models. Leading instrument developers are investing in modular architectures that support multiple assay workflows, while reagent and consumable suppliers are concentrating on antibody validation, reagent stabilization, and lot-to-lot consistency to reduce variability in downstream data. Contract research organizations and specialized service providers are becoming strategic partners for organizations that lack in-house capacity to run large-scale immune monitoring or complex tissue-based assays, offering assay development, sample processing, and data analysis as bundled services.

Collaborations between diagnostics companies and pharmaceutical sponsors are increasingly common, driven by the need for companion diagnostics that can stratify patients and support therapeutic approval pathways. At the same time, smaller innovators are carving niches by delivering highly multiplexed assays, advanced single-cell analytics, or streamlined automation aimed at specific clinical workflows. Cross-sector partnerships, including academic spin-outs and instrument-reagent co-development agreements, are central to advancing assay robustness and accelerating clinical validation. Overall, competitive dynamics emphasize interoperability, quality assurance, and the ability to provide end-to-end solutions that reduce the barriers for clinical and translational adoption.

Actionable recommendations for industry leaders focusing on validation rigor, workflow-centric design, supply chain resilience, regulatory engagement, and data harmonization to accelerate adoption

Leaders in the field should prioritize a set of pragmatic, actionable measures to convert innovation into operational impact. First, invest in rigorous assay validation pathways that address analytical performance, reproducibility across sites, and traceability of reagents. This foundational work reduces downstream clinical risk and simplifies regulatory engagement. Second, design product and service offerings with the end-user workflow in mind: automation, user-friendly software, and interoperability with laboratory information systems accelerate adoption in diagnostic and clinical environments. Third, strengthen supply chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and maintaining strategic inventory buffers for critical reagents to mitigate disruptions from trade policy changes and logistical constraints.

Fourth, engage early with clinical and regulatory stakeholders to align validation plans with approval and reimbursement expectations. Fifth, cultivate partnerships with academic centers and CROs to support multicenter validation studies and to access diverse patient cohorts. Sixth, invest in data harmonization and bioinformatics expertise to deliver clinically interpretable outputs from complex multi-omic assays. Implementing these recommendations in a coordinated fashion enhances the likelihood that new assays will achieve both scientific credibility and practical utility across research and clinical settings.

A transparent, expert-driven research methodology combining stakeholder interviews, technical synthesis, and iterative expert review to ensure actionable and defensible insights

The research methodology underpinning this analysis integrates primary stakeholder engagement, secondary literature synthesis, and cross-functional expert review to ensure rigor and relevance. Primary inputs include interviews with scientific leaders, laboratory directors, and commercial executives who bring firsthand perspectives on assay performance, deployment challenges, and adoption drivers. These qualitative insights are triangulated with technical literature and regulatory guidance to ground conclusions in current best practices and emerging standards.

Analytical approaches emphasize comparative technology assessment, evaluation of product lifecycle considerations, and scenario-based exploration of supply chain and regulatory variables. Special attention is paid to reproducibility benchmarks, validation frameworks, and implementation barriers across academic, clinical, and commercial settings. Findings were iteratively reviewed by subject-matter experts to refine strategic implications and to ensure that recommendations are actionable for stakeholders pursuing assay development, commercialization, or clinical integration.

Conclusion synthesizing technological progress, operational constraints, and strategic imperatives that determine which immuno-oncology assays will achieve clinical and commercial impact

In conclusion, immuno-oncology assays are transitioning from a predominantly exploratory toolkit toward a set of clinically relevant, operationally scalable solutions that can materially influence therapeutic development and patient care. The convergence of enhanced multiplexing, single-cell resolution, sequencing depth, and automation is expanding what is measurable and interpretable, while supply chain realities and regulatory expectations are shaping how assays are developed and deployed. Successful strategies will balance technological ambition with pragmatic considerations of validation, reproducibility, and end-user workflow integration.

Looking ahead, organizations that invest in robust assay validation, cultivate strategic partnerships, and design solutions that address real-world clinical and laboratory constraints will be best positioned to convert scientific advances into measurable clinical and commercial value. The ability to harmonize data across platforms and to translate complex multi-dimensional readouts into clinically meaningful insights will be the defining capability for leaders in this space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of high-content imaging assays for simultaneous analysis of immune cell phenotypes and functions in tumor microenvironment
  • 5.2. Development of liquid biopsy-based assays for noninvasive monitoring of immune checkpoint inhibitor efficacy in cancer patients
  • 5.3. Expansion of multiplexed cytokine profiling platforms enabling detailed assessment of immunotherapy-induced biomarkers in real time
  • 5.4. Advancements in single-cell sequencing assays to characterize T-cell receptor diversity and clonality in response to immunotherapy
  • 5.5. Commercialization of standardized PD-L1 IHC assays with digital pathology integration for improved predictive accuracy
  • 5.6. Emergence of neoantigen-based peptide proliferation assays to personalize cancer vaccine development and patient selection
  • 5.7. Adoption of automation and microfluidics in immunoassays to increase throughput and reproducibility in clinical trial settings
  • 5.8. Regulatory guidelines evolution for companion diagnostic immunoassays aligning with novel immune checkpoint targets and combinations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno Oncology Assays Market, by Technology Type

  • 8.1. Flow Cytometry
    • 8.1.1. Conventional Flow Cytometry
    • 8.1.2. Spectral Flow Cytometry
  • 8.2. Immunoassay
    • 8.2.1. Elisa
    • 8.2.2. Multiplex Immunoassay
  • 8.3. Mass Cytometry
  • 8.4. Next Generation Sequencing
    • 8.4.1. Targeted Panel
    • 8.4.2. Whole Exome Sequencing
    • 8.4.3. Whole Genome Sequencing

9. Immuno Oncology Assays Market, by Product

  • 9.1. Consumables
    • 9.1.1. Probes And Antibodies
    • 9.1.2. Reagents And Kits
  • 9.2. Instruments
    • 9.2.1. Automated Systems
    • 9.2.2. Platform Based Instruments

10. Immuno Oncology Assays Market, by Sample Type

  • 10.1. Blood
  • 10.2. Cell Lines
  • 10.3. Tissue

11. Immuno Oncology Assays Market, by End User

  • 11.1. Academic And Research Institutes
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical And Biotech

12. Immuno Oncology Assays Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Hematologic Cancers
  • 12.3. Lung Cancer
  • 12.4. Melanoma

13. Immuno Oncology Assays Market, by Application

  • 13.1. Biomarker Discovery
  • 13.2. Companion Diagnostics
  • 13.3. Cytokine Analysis
  • 13.4. Immune Monitoring
  • 13.5. Tumor Microenvironment Analysis

14. Immuno Oncology Assays Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno Oncology Assays Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno Oncology Assays Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Danaher Corporation
    • 17.3.3. Merck KGaA
    • 17.3.4. Agilent Technologies, Inc.
    • 17.3.5. Reaction Biology Corporation
    • 17.3.6. Bio-Rad Laboratories, Inc.
    • 17.3.7. Creative Biolabs
    • 17.3.8. QIAGEN N.V.
    • 17.3.9. Illumina, Inc.
    • 17.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNO ONCOLOGY ASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2025-